-
Block trade completed off-market
-
Biofrontera enters essential growth phase with long-term investors
Leverkusen, 08 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical company focusing on skin cancer, has stabilized its shareholder structure through an off market block trade of shares. Following intensive selling over the stock markets, the one million remaining shares owned by Dr. Carsten Maschmeyer, through his investment funds, were acquired by existing institutional investors in Biofrontera.
"Biofrontera is in an important growth phase. Developments in 2015 will be core to our future success, in particular with the preparations for the market entry of Ameluz in the USA. In addition, we will progress the indication expansion for basal cell carcinoma in Europe as quickly as possible. In this phase we are delighted by the confidence of investors taking up a block of shares on short notice, signalling their support for the Company`s strategy." said Biofrontera`s CEO, Prof. Hermann Lübbert.
The shareholder structure of Biofrontera AG is published and regularly updated on Biofrontera`s homepage within the relevant reports.
Ends
Enquiries, please contact:
| Biofrontera AG | +49 (0) 214 87 63 2 0 |
| IR Germany: Brainwell Asset Solutions | +49 (0) 152 08931514 |
| Nomad and Broker: Shore Capital | +44(0) 20 7408 4090 |
| IR UK: Seton Services | +44(0) 20 7603 6797 |
| Financial PR: Gable Communications | +44(0) 20 7193 7463 |
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera`s most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® cream, gel and scalp tonic are available through Amazon.